Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB, a global biopharmaceutical company, today announced the first analyses of pooled data...

Related Keywords

Germany ,Belgium ,Brussels ,Bruxelles Capitale ,Berlin ,Hidradenitis Suppurativa ,Emmanuel Caeymaex ,Klinikum Dessau ,J Clin Pharmacol ,Nicole Herga ,Antje Witte ,European Academy Of Dermatology ,Drug Administration ,Us Communications ,European Hidradenitis Suppurativa Foundation ,Brandenburg Medical School ,International Hidradenitis Suppurativa Severity Score System ,Immunology Solutions ,Twitter ,Analysis Presented ,Bimekizumab Achieved High Thresholds ,Clinical Response ,Executive Vice President ,Professor Christos ,Founding Professor ,Last Observation Carried ,Euronext Brussels ,Study Participants With Moderate ,Severe Hidradenitis Suppurativa ,Rev Dis ,Perceived Stigma ,Self Stigma In Patients With Hidradenitis ,Clin Cosmet Investig ,Its Effect ,